Comparison of the 2021 COVID-19 Roadmap Projections Against Public Health Data in England

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Aug 22

PMID 35995764

Authors

Matt J Keeling

Louise Dyson

Michael J Tildesley

Edward M Hill

Samuel Moore

Affiliations

Soon will be listed here.

Abstract

Control and mitigation of the COVID-19 pandemic in England has relied on a combination of vaccination and non-pharmaceutical interventions (NPIs). Some of these NPIs are extremely costly (economically and socially), so it was important to relax these promptly without overwhelming already burdened health services. The eventual policy was a Roadmap of four relaxation steps throughout 2021, taking England from lock-down to the cessation of all restrictions on social interaction. In a series of six Roadmap documents generated throughout 2021, models assessed the potential risk of each relaxation step. Here we show that the model projections generated a reliable estimation of medium-term hospital admission trends, with the data points up to September 2021 generally lying within our 95% prediction intervals. The greatest uncertainties in the modelled scenarios came from vaccine efficacy estimates against novel variants, and from assumptions about human behaviour in the face of changing restrictions and risk.

Citing Articles

Understanding Nash epidemics.

Schnyder S, Molina J, Yamamoto R, Turner M Proc Natl Acad Sci U S A. 2025; 122(9):e2409362122.

PMID: 40014574 PMC: 11892628. DOI: 10.1073/pnas.2409362122.

A retrospective assessment of forecasting the peak of the SARS-CoV-2 Omicron BA.1 wave in England.

Keeling M, Dyson L PLoS Comput Biol. 2024; 20(9):e1012452.

PMID: 39312582 PMC: 11449292. DOI: 10.1371/journal.pcbi.1012452.

Prioritising older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings.

Bouros I, Hill E, Keeling M, Moore S, Thompson R PLoS Comput Biol. 2024; 20(8):e1012309.

PMID: 39116038 PMC: 11309497. DOI: 10.1371/journal.pcbi.1012309.

Recent approaches in computational modelling for controlling pathogen threats.

Lees J, Russell T, Shaw L, Hellewell J Life Sci Alliance. 2024; 7(9).

PMID: 38906676 PMC: 11192964. DOI: 10.26508/lsa.202402666.

Improving modelling for epidemic responses: reflections from members of the UK infectious disease modelling community on their experiences during the COVID-19 pandemic.

Sherratt K, Carnegie A, Kucharski A, Cori A, Pearson C, Jarvis C Wellcome Open Res. 2024; 9:12.

PMID: 38784437 PMC: 11112301. DOI: 10.12688/wellcomeopenres.19601.1.

References

Borchering R, Mullany L, Howerton E, Chinazzi M, Smith C, Qin M . Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: A multi-model study. Lancet Reg Health Am. 2022; 17:100398. PMC: 9679449. DOI: 10.1016/j.lana.2022.100398. View

Harris R, Hall J, Zaidi A, Andrews N, Dunbar J, Dabrera G . Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J Med. 2021; 385(8):759-760. PMC: 8262621. DOI: 10.1056/NEJMc2107717. View

Keeling M, Moore S . An assessment of the vaccination of school-aged children in England against SARS-CoV-2. BMC Med. 2022; 20(1):196. PMC: 9113775. DOI: 10.1186/s12916-022-02379-0. View

Keeling M, Hill E, Gorsich E, Penman B, Guyver-Fletcher G, Holmes A . Predictions of COVID-19 dynamics in the UK: Short-term forecasting and analysis of potential exit strategies. PLoS Comput Biol. 2021; 17(1):e1008619. PMC: 7857604. DOI: 10.1371/journal.pcbi.1008619. View

Tkachenko A, Maslov S, Wang T, Elbana A, Wong G, Goldenfeld N . Stochastic social behavior coupled to COVID-19 dynamics leads to waves, plateaus, and an endemic state. Elife. 2021; 10. PMC: 8670744. DOI: 10.7554/eLife.68341. View

Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J . Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538). PMC: 8128288. DOI: 10.1126/science.abg3055. View

Funk S, Bansal S, Bauch C, Eames K, Edmunds W, Galvani A . Nine challenges in incorporating the dynamics of behaviour in infectious diseases models. Epidemics. 2015; 10:21-5. DOI: 10.1016/j.epidem.2014.09.005. View

Baker R, Yang W, Vecchi G, Metcalf C, Grenfell B . Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic. Science. 2020; 369(6501):315-319. PMC: 7243362. DOI: 10.1126/science.abc2535. View

Farmer R, Mathur R, Bhaskaran K, Eastwood S, Chaturvedi N, Smeeth L . Promises and pitfalls of electronic health record analysis. Diabetologia. 2017; 61(6):1241-1248. PMC: 6447497. DOI: 10.1007/s00125-017-4518-6. View

10.

Davies N, Barnard R, Jarvis C, Russell T, Semple M, Jit M . Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. Lancet Infect Dis. 2020; 21(4):482-492. PMC: 7758181. DOI: 10.1016/S1473-3099(20)30984-1. View

11.

Ozair F, Jamshed N, Sharma A, Aggarwal P . Ethical issues in electronic health records: A general overview. Perspect Clin Res. 2015; 6(2):73-6. PMC: 4394583. DOI: 10.4103/2229-3485.153997. View

12.

Buckee C, Noor A, Sattenspiel L . Thinking clearly about social aspects of infectious disease transmission. Nature. 2021; 595(7866):205-213. DOI: 10.1038/s41586-021-03694-x. View

13.

Moore S, Hill E, Tildesley M, Dyson L, Keeling M . Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. Lancet Infect Dis. 2021; 21(6):793-802. PMC: 7972312. DOI: 10.1016/S1473-3099(21)00143-2. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881-891. PMC: 7894131. DOI: 10.1016/S0140-6736(21)00432-3. View

15.

Knock E, Whittles L, Lees J, Perez-Guzman P, Verity R, FitzJohn R . Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. Sci Transl Med. 2021; 13(602). PMC: 8432953. DOI: 10.1126/scitranslmed.abg4262. View

16.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

17.

Borchering R, Viboud C, Howerton E, Smith C, Truelove S, Runge M . Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States, April-September 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(19):719-724. PMC: 8118153. DOI: 10.15585/mmwr.mm7019e3. View

18.

Keeling M, Dyson L, Tildesley M, Hill E, Moore S . Comparison of the 2021 COVID-19 roadmap projections against public health data in England. Nat Commun. 2022; 13(1):4924. PMC: 9395530. DOI: 10.1038/s41467-022-31991-0. View

19.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

20.

Pouwels K, Pritchard E, Matthews P, Stoesser N, Eyre D, Vihta K . Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021; 27(12):2127-2135. PMC: 8674129. DOI: 10.1038/s41591-021-01548-7. View